/PRNewswire/ Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use.
Omega Therapeutics Announces Pricing of Initial Public Offering
News provided by
Share this article
Share this article
CAMBRIDGE, Mass, July 29, 2021 /PRNewswire/ Omega Therapeutics, Inc. (Nasdaq: OMGA) ( Omega ), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming™ platform to harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines, today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Omega. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Omega, are expected to be approximately $125.8 million, excluding any exercise of the underwriters option to purchase additional shares. Omega s common stock is expected to begin trading on the Nasdaq
Share this article
Share this article
CAMBRIDGE, Mass., May 20, 2021 /PRNewswire/ Omega Therapeutics, Inc. ( Omega ), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming™ platform to harness the power of epigenetics and pioneer novel DNA-sequence-based targets and develop a new class of mRNA-encoded programmable epigenetic medicines, today announced the appointment of Elliott M. Levy, M.D., to its Board of Directors. Dr. Levy is an industry veteran with over 20 years of research and development experience at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb. Elliott s extensive leadership experience in spearheading research and development strategy and operations at all stages of clinical development is a valuable addition to our team as we focus our efforts on further expanding the potential of our OMEGA platform across a broad array of diseases. Through his professional career at major pharmaceutical companies, Ellio